InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Search
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Gerhard Kraus, Global Head of IT Infrastructure
Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Boehringer Ingelheim supports collaboration and knowledge sharing in the livestock industry
Boehringer Ingelheim demonstrates its commitment to farm animal well-being by organising its 11th Expert Forum on Farm Animal Well-Being
It Takes 2
It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Animal Health Partnering Interests Infectious Diseases May 2024 CORP
Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP
Animal Health Partnering Interests CNS Diseases May 2024 CORP
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
The impact of A Life in a Day of a patient
A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
Partnership Boehringer Ingelheim Lifebit health data
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Our core product areas
Our core product areas
Our core product areas
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.